TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics ...

TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

Regeneron Pharmaceuticals already has a presence in immunology, but nothing in its portfolio or pipeline addresses inflammatory bowel disorders nor does the drugmaker have any cell therapies. The ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...

A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor. Colorectal cancer, however ...

California biotech Sangamo Therapeutics has given its first doses of an experimental cell therapy. The company is developing a new type of medicine for autoimmune diseases called CAR-Tregs. Its ...

Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this ...